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Introduction  
According to the most recent World Health Organization (WHO) Global TB Report the estimated 
annual tuberculosis (TB) incidence decreased globally by an average of 1.5% per year since 2000 
and the estimated TB prevalence in 2014 was 42% lower than in 1990 [1]. However, an estimated 
9.6 million people worldwide developed active TB in 2014, among them 12% being HIV-infected 
[1]. During the same year TB caused 1.5 million deaths, making it the commonest cause of death 
from an infectious disease. 
In 2014, a total of 329,270 TB cases were reported from 51 countries in the WHO European Region 
(notification rate: 36.7 cases per 100,000 population), with 33,000 estimated deaths [2]. The 
estimated incidence in Europe represents 3% of the global TB burden. 
  
TB is considered a major public health challenge in many countries worldwide, particularly among 
vulnerable populations, such as individuals at higher risk of exposure to discrimination, hostility or 
economic adversity. These factors unfortunately afflict the lives of many migrants and refugees 
(here defined in agreement with the 1951 ‘Convention and Protocol relating to the status of 
Refugees’ http://www.unhcr.org/3b66c2aa10.html)[1-5].  
 
Several factors have contributed to increase population mobility in the WHO European Region, 
such as the establishment of the European Union (EU) and free movement within the Newly 
Independent States (NIS), particularly for seasonal labour [5,6]. This increased population mobility 
poses challenges for TB control and requires effective and sustainable mechanisms to ensure quality 
TB and Latent TB Infection (LTBI) prevention, diagnosis and treatment [5,7]. 
The need for coordinated intervention in these areas is justified from the perspective of individual 
human rights (independent of legal or residential status of the subject) as well as public health pre-
requisites to control and ultimately eliminate TB, including multi- and -extensively drug resistant 
TB (MDR- and XDR-TB) [3,8-10]. 
For undocumented migrants, full access to TB diagnosis and treatment (with guarantee of protection 
from deportation until the end of treatment) has been recommended by WHO; this is in the interest 
of both the individual and the wider hosting community in terms of TB control and elimination [11-
15]. 
 
In 2015 more than one million migrants and refugees reached Europe by land and sea. In 2014 the 
estimated figure was significantly lower (219,000) [4,16].  
According to official data, between January 1st and April 12, 2016, an estimated 173,728 new 
migrants arrived in Europe, with 716 reported deaths; Eighty-two percent of arrivals in the 
Mediterranean sea originate from the top 10 countries which are the origin of most refugees [16].  
At the current time, the four countries from which most refugees originate are: the Syrian Arab 
Republic (43% of the overall flow), Afghanistan (23%), Iraq (14%), Pakistan (4%) and Iran (4%).  
(see also: http://ec.europa.eu/eurostat/statistics-
explained/index.php/File:First_time_asylum_applicants_in_the_EU-
28_by_citizenship,_Q4_2014_%E2%80%93_Q4_2015.png) 
Despite the recent release of resolutions and statements by bodies such as WHO, the European 
Respiratory Society (ERS) and the EU [4,17], not much is known about the policies in force in the 
European countries with regards to TB and LTBI management among refugees upon arrival. 
 
In light of the ongoing refugee situation in Europe, the aim of this ERS/WHO European Region 
study (performed through the ERS ad hoc Working Group on TB Advocacy) is to	document the 
policies and practices of low and intermediate TB incidence European countries	with regards to 
detection and management of TB and LTBI among refugees. 
 
Methods 
Survey Questionnaire 
In September-October 2015, experts from the ERS, WHO Regional Office for Europe and the 
WHO Collaborating Centre in Tradate, Italy, as members of the ERS ad-hoc Working Group on TB 
Advocacy, (http://www.ersnet.org/index.php?option=com_flexicontent&view=items&id=5200-tb-
advocacy-working-group.html accessed 12 April 2016) developed a short questionnaire for a rapid 
survey containing multiple choice and open-ended questions on screening and management of TB 
and LTBI among refugees in Europe. The questionnaire was finalized after reviewing suggestions 
and comments received from the members of the ERS TB Advocacy ad-hoc Working Group and 
reaching overall consensus among the members. In addition to basic demographic data of the 
respondents, the survey comprised questions on the following subject areas: screening for, and 
management of TB/LTBI; guidelines, legislation and evidence for current practice; cross-border TB 
care; organisational aspects of TB care and infection control measures. 
 
The questionnaire was sent to the national TB programme representatives of all European Union/ 
European Economic Area countries of the WHO European Region, Switzerland and six other 
countries who have hosted, or were deemed likely to host, or become a transient country for a 
significant number of refugees in the near future. The six additional countries were the current EU 
candidate countries (Albania, Bosnia and Herzegovina, the former Yugoslav Republic of 
Macedonia, Montenegro, Serbia and Turkey). The survey, along with a cover letter for additional 
information, was sent to each of the national TB programme representatives on 23rd October 2015 
with an initial deadline set for 6th November 2015. Furthermore, there was an offer for the TB 
programme representatives to conduct a telephone interview to complete the survey, should 
returning the document prove too difficult by the deadline provided. On 9th November 2015 a 
reminder email was sent to programme representatives who had not responded. The survey was 
closed on February 24th 2016. 
 
Data Analysis 
The results of the survey were entered into a Microsoft Excel programme (Excel 2010, Microsoft 
Corporation, Albuquerque, New Mexico, USA) and double-checked (LDA; RC) prior to analysis. 
Results produced a mixture of quantitative and qualitative data, with descriptive statistics being 
calculated where appropriate, and supplemented with qualitative information provided by 
responders to the survey. 
 
Ethics 
As a broad evaluation of current policies and practices within countries, ethical approval was not 
required because the study did not collect individualized information on subjects. 
 
Results 
36 out of 38 (94.7%) countries contacted responded to the questionnaire (all except Poland and 
Bosnia-Herzegovina) 
The results from Section 1 (Screening for TB and LTBI among refugees in the European Region) 
are summarized in Table 1. 
-	Refugees are routinely screened for active TB by the majority of the countries (30/36, 83.3%), 
with the exception of Italy, Monaco and Portugal	where a non-systematic	screening is performed 
(only in symptomatic individuals); in Germany refugees are only screened for active TB if they are 
to be accepted into a shared accommodation, while no screening is performed in Former Yugoslavia 
Republic of Macedonia (length of stay in holding center is not long enough for screening to take 
place) and Serbia ( insufficient governmental funding).	 
Nineteen countries (52.7%) screen systematically for LTBI among refugees, eight countries 
(22.2%) (Denmark, Finland, Germany, Italy, Monaco,	Netherlands, Portugal and Slovenia (this one 
reporting low numbers)) do not perform it systematically and nine (25%) do not screen at all for 
LTBI (Albania, Austria, Czech Republic, Hungary, Ireland,  Latvia, Former Yugoslav Republic of 
Macedonia, Serbia and Switzerland) (Figure 1). 
However, almost half of the countries (8/17, 47%) that currently do not screen for TB and LTBI 
have plans to introduce it for TB and/or LTBI in the near future.	There is a legal obligation to 
screen for TB and/or LTBI in 21 of the 36 (58.3%) countries responding to this survey. 
Screening for TB is performed with algorithms using different combinations of symptom-based 
questionnaires (21/36, 58.3% of which one not systematically collected), bacteriology (18/36, 50% 
sputum smear/culture collection of which nine for symptomatic individuals only) and chest 
radiography (26/36, 72.2% of which two perform not systematically); six countries (Denmark, 
Germany, Italy, Monaco, Portugal and Turkey) do not systematically perform any TB specific 
examination, while one country (Spain) starts the algorithm with tuberculin skin tests (TST) and 
blood test. 
In two countries (Croatia and Hungary) routine bacteriology for TB is part of the screening 
procedure. 
Similar to the findings described by a previous ERS/WHO Europe Region Study [10], LTBI 
screening is performed by using different combinations of TST and Interferon-γ Release Assays 
(IGRAs) in 23/36 (63.8%) different European countries (8/36, 22.2% TST only, 11/36, 30.5%, TST 
plus IGRA, 4/36, 11.1% TST plus IGRA in selected cases). 
In 22/36 (61.1%) countries, TB and LTBI screening are performed in refugee centres, using also 
other combinations of measures (See Table 1 for details). 
The decision to perform TB/LTBI screening is determined by the TB incidence rate in the country 
of origin of refugees in 14/36 (38.8%) of the surveyed countries. No single threshold was provided. 
In the majority of countries where any screening takes place, it is performed only once (28/30; 
93.3%). 
The results from Section 2 (Management of TB and LTBI among refugees in Europe) are 
summarized in Table 2. 
In the majority of countries (24/36, 66.6%) treatment after diagnosis of active TB in a refugee is 
required, whereas in Denmark, Monaco, Netherlands and Portugal the TB treatment is voluntary; in 
six other countries (Belgium, Germany, Ireland, Sweden, Switzerland, and UK)  individuals cannot 
be legally forced to take medications, but can usually be convinced to start anti-TB treatment; 
involuntary isolation is foreseen in case of  refusal to comply with treatment, while in Serbia 
isolation is only considered for MDR-TB patients who refuse treatment, and in Macedonia no TB 
treatment is proposed due to the short length of stay in the country. Overall, no EU country reported 
that TB detection was a reason for deportation. 
Anti-TB treatment is proposed immediately after diagnosis in the majority of countries (26/36, 
72.2%), where its costs are covered by central governmental funds (26/36, 72.2%).  
Almost a third of countries (23/36, 63.8%) report that efforts are ongoing to adapt TB services to 
refugees’ specific needs through specific national/regional programmes and improved cooperation 
with the non-governmental sector. 
A similar number of countries (22/36, 61.1%), directly or indirectly [through certified non-
governmental organizations (NGOs)] allow undocumented refugees access to TB services. 
Among countries with general or specific regional/national programmes (or guidelines) for TB 
management in refugees (14/36,	38.8%), more than half (9/14, 64.2%) report difficulties in fully 
complying with requirements of their own guidelines, given the high number of refugees in the 
present situation. 
Further details on specific national programmes are available in Table 2. 
The results from Section 3 (Guidelines, Legislation and Evidence on the results of screening and 
treatment of TB and LTBI in Europe) are summarized in Table 3. 
In particular, 27/36 (75%) countries answered that screening for TB is done as per national and 
international guidelines (offering the same services to refugees and nationals), while 19/36 (52.7%) 
gave the same answer with regards to LTBI screening.  
Similarly, while 22/36 (61.1%) countries confirmed that they collect data on the yield of active TB 
screening among refugees (with Estonia, Finland, Norway and the UK partially/not systematically 
collecting data), only 11/36 (30.5%) countries (Bulgaria, Finland, France, Iceland, Italy, Lithuania, 
Norway, Slovakia, Slovenia, Turkey and UK) are equipped to collect similar data for LTBI 
screening (Finland, Norway and the UK providing data not systematically). 
Finally, detailed information on TB treatment outcomes is available in 19/36 (52.7%) countries, 
while treatment completion rates for LTBI therapy among refugees are available in only 8 (22.2%) 
countries (Bulgaria, France, Iceland, Netherlands, Portugal, Slovakia and Slovenia and Turkey). 
The results from Section 4 (Organisational aspects of TB care and infection control issues) are 
summarized in Table 4. 
Seven (19.4%) countries (Austria, Croatia, Germany, Greece, Former Yugoslavia Republic of 
Macedonia, Serbia and Turkey) reported to host > 250,000 refugees in the 6 months preceding the 
survey, Hungary notified a range between 100,001 and 250,000, while Italy and Sweden reported 
hosting between 50,001 and 100,000 refugees. 
In the vast majority of the countries (30/36, 83.3%) the public sector services are in charge of 
managing refugees for TB-related issues, complemented by international organisations (e.g. Red 
Cross in Bulgaria, Denmark, Former Yugoslavia Republic of Macedonia, Serbia and Spain, the 
International Organization for Migration in Romania and Medicine du Monde in UK). 
Several problems were reported among the different countries, including internal and external 
communication and coordination issues, cultural mediation/language differences and inadequate 
funding or human resources. The sheer volume of refugees	was also cited as a challenge in eight 
(22.2%) countries (Austria, Belgium, Germany, Greece, Italy, Netherlands, Norway, Serbia) to deal 
with.  
Although respirators are generally available to protect staff and complement administrative 
infection control measures, a general lack of consistency with international guidelines emerges from 
the countries’ answers. 
Discussion 
The aim of our study was to investigate which policies and practices exist for TB and LTBI 
screening and management among refugees in low and intermediate TB incidence countries of 
Europe.  
The survey had a very high response rate (36/38,	94.7%) which shows countries’ interest and 
prioritisation of this issue.  
The results of our study confirm that screening for TB is considered as an important public health 
measure in Europe, although significant differences exist in screening practices among countries. 
According to a survey conducted in 2012 on screening practices on infectious diseases	among 
newly arrived migrants to Europe, all countries perform TB screening, with the second most 
screened condition being  Hepatitis B (30% of the countries) [18].    
The results of our survey also indicate that there is a general lack of analysis of the yield of TB and 
LTBI screening among refugees. The huge workload is assumed as the main reason. Furthermore, 
much less information is available for LTBI than for active TB disease. 
While our survey shows that 30 countries regularly screen refugees for TB, only 19 screen for 
LTBI, and even a fewer report outcomes of LTBI treatment [9]. 
The large number of arrivals in holding centres, particularly in some European countries, makes 
LTBI screening and subsequent management problematic. In addition, several countries reported 
difficulties in coordination between holding centres and TB services serving the native population. 
Based on our survey, it appears that there are no systematic follow-up screening/check-ups of 
refugees for TB sometime after their arrival. Given that refugees are often exposed to precarious, 
stressful travelling conditions during transit – which provide a risk of Mycobacterium tuberculosis 
transmission-, there is a need to ensure people-centred care is available to them	beyond arrival in 
their host country. Symptomatic screening of refugees and more intensive follow-up for those with 
LTBI may be justified. This is particularly important as many European countries are scaling-up 
their efforts to eliminate TB [10]. 
In an attempt to make screening as cost-effective as possible, countries have applied different 
algorithms in line with WHO recommendations [19]. They are based on different combinations of: 
symptom-based questionnaires, bacteriology and chest radiography (Table 2). 
Evaluation of the yield of these screening procedures was beyond the scope of this study, however 
there is a real need for analysis of such data at national and regional level [5,6]. 
Our study identified different models of screening for TB/LTBI in Europe. Some countries perform 
radiological screening of all migrants in a hub or holding center, and carry out further investigations 
in decentralised centres only if radiological abnormalities are identified. Others implement different 
screening algorithms or organise provision of health services differently at the refugee centres. 
In this context, screening for LTBI by use of IGRAs and/or TST- although considered an important 
intervention in the pursuit of TB Elimination [9,10] is still difficult to implement in several 
countries. 
Based on the unprecedented number of refugees, it is important to have a specific response plan and 
ensure its full funding both at the national and European level. 
Interestingly, in the majority of countries (22/36, 61.1%), TB services are organised in collaboration 
with NGOs and other sectors. Among others benefits, this approach has the advantage of increasing 
cultural sensitivity of the TB services.  
Infection control measures are generally inadequate in a large proportion of the countries surveyed. 
Surgical masks are often used to ‘protect’ health care workers when it is well known that they are 
ineffective against M. tuberculosis from active TB patients who are not on treatment; certified 
respirators are needed for this purpose. Furthermore, a lack of specific training on infection control 
measures has been reported. Similar problems have previously been described in European MDR-
TB reference centres [20]. 
Although surveys of this kind are subject to several limitations (related to the instrument used, the 
missing information from non-responding countries, the possible erroneous responses from national 
programmes and the limitations of aggregated data), strengths of this study include: continuous 
dialogue with National TB representatives; the very high response rate (94.7%); and the consistency 
of the answers received with previous surveys carried out using similar methodology [10]. 
The results of the present study highlight the need for improved coordination of TB screening in 
Europe, with the ultimate goal of implementing the End TB Strategy, the TB Action Plan for the 
WHO European Region 2016-2020 [21] and the Health 2020 Policy Framework [22] to address 
inequity. The ultimate goal of these strategies is to achieve TB Elimination [9,10,23,24].  
This will require quality operational research evaluating surveillance (aimed at attaining better data 
for better planning), the efficacy of existing algorithms and the yield of screening activities [25]. 
Furthermore, within the limited information available on LTBI in the European context, further 
clinical and operational research is also needed to inform clinicians and public health authorities on 
the correct approach to follow when LTBI is diagnosed in contacts of MDR-TB cases. 
Finally, the new function of the ERS/WHO Europe TB Consilium (a free-cost, internet-based 
instrument supporting clinicians to manage difficult-to-treat cases of tuberculosis) is now live and 
accessible under the TB Consilium website (www.tbconsilium.org). This electronic platform will 
allow better cross-border TB control by contributing to the provision of quality prevention, 
diagnostic and treatment services to migrants and refugees. 
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Figure 1: Graphical summary of the countries screening for tuberculosis (TB) and Latent 
Tuberculosis Infection (LTBI) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Questionnaire Section I: Screening for TB and LTBI among refugees in Europe 
Active	TB	
screening	
Yes/No	
LTBI	
screening	
Yes/No	
Plans	to	
implement	
screening	
for	active	
TB	/	LTBI	
				Yes/No	
	
	
Legal	
requirem
ent	for	
screenin
g	
Yes/No	
Active	TB	screening	
performed	by:	
-	Symptomatic	
questionnaire		
-	Sputum	collection		
-	Chest	radiography	
-	Other		
Routinely	
sputum	
collection	for	
microbiological	
study/culture/	
Xpert	
										Yes/No	
LTBI	screening	
performed	by:	
-	TST	
-	IGRA		
-	Other	
Place	of	screening:	
-	Pre-arrival		
-	On	arrival		
-	In	refugees	centres		
-	In	the	community		
-	Other	
Information	
on	TB	rates	in	
the	country	
of	origin	to	
decide	for	the	
screening	
process	
Yes/No	
Screenings	
Number	
1,2…	
Yes	
30/36	
(83.3%)	
	
Yes	
19/36	
(52.7%)	
Yes	
8/17*	
(47%)	
Yes	
21/36	
(58.3%)	
	
	
Yes	
systematic		
symptoms-based	
questionnaires		
							20/36	(55.5%)	
	
Yes	
not	systematic	
symptoms-based	
questionnaire	
1/36	(2.7%)	
	
Yes	
systematic	
bacteriology		
9/36	(25%)	
	
	Yes	
bacteriology	for	
symptomatic	
individuals	only	
											9/36	(25%)	
Yes	
										2/36	
(5.5%)	
Yes		
TST	
19/36	(52.7%)	
	
Yes		
TST	only	
8/36	(22.2%)	
	
										Yes	
TST	plus	IGRA	
11/36		(30.5%)	
	
Yes	
not	systematic	
TST	plus	IGRA		
4/36	(11.1%)	
	
Refugees	centres	only	
10/36	(27.7%)	
	
On	arrival	only	
4/36	(11.1%)	
	
In	the	community	only	
1/36	(2.7%)	
	
In	the	National		
TB	Programme	Centre	
only	
1/36	(2.7%)	
	
On	arrival		
and	in	refugees	centres	
6/36	(16.6%)	
	
On	arrival		
and	at	pre-arrival	
	1/36	(2.7%)	
	
Yes	
14/36	(38.8%)	
	
	
	
Only	once	
28/30)#	
(93.3%)	
	
More	than	
once	
3/30#	
(10%)	
	
.	
	
Yes	
systematic		
chest	radiography		
24/36	(66.6%)	
	
Yes	
not	systematic		
chest	radiography	
2/36	(5.5%)	
	
	
	
On	arrival	and	in	the	
community	
1/36	(2.7%)	
	
On	pre-arrival	and	in	the	
community	
	1/36	(2.7%)	
	
In	refugees	centres		
and	in	the	community	
6/36	(16.6%)	
	
Not	applicable	
information	
5/36	(13.8%)	
	
No	
2/36	
(5.2%)	
No	
9/36	
(25%)	
	
No	
5/17*	
(29.4%)	
	
No	
12/36	
(33.3%)	
Other	procedures	§	
1/36	(2.7%)	
	
No	
34/36	
(94.4%)	
Not	applicable	
(for	both)	
13/36	(36.1%)	
	 No	
19/36	(52.7%)	
	
	
	
Not	
sistematic
ally	
4/36	
(11.1%)	
	
Not	
sistemati
cally	
8/36	
(22.2%)	
	
Not	
answered	
3/17*	
(17,6%)	
	
Not	
applicabl
e	
3/36	
(13.8%)	
	
Not	systematic	
screening	for	active	TB	
	6/36	(16.6%)**	
											
	 	 	 Not	
applicable	
3/36	(13.8%)	
	
	 	 Not	
applicable	
1/17*	
(5.9%)	
	 	 	 	 	 	 	
Footnotes:	TB:	tuberculosis;	LTBI:	latent	Tuberculosis	infection;	TST:	tuberculin	skin	test;	IGRA:	Interferon-Gamma	Release	Assays;	*denominator	is	the	number	
of	countries	that	do	not	(and	not	systematically)	screen	for	TB/LTBI;	§:	initial	algorithm	with	tuberculin	skin	tests	(TST)	and	blood	examination;	#:	denominator	
is	the	number	of	countries	that	screen	for	TB/LTBI;	**:	numerator	includes	countries	which	do	not	systematically	perform	any	examination		
Table 2: Questionnaire Section II: Management of TB and LTBI among refugees in Europe 
Procedures	if	
active	TB	is	
diagnosed:	
-	Refusal	of	
asylum	
-	Obligation	to	
undergo	
treatment	
-Other	
	
	
Obligation	to	
undergo	
treatment:	
a.	Where	
b.	When	
c.	Funding	
Procedures	if		
LTBI	is	
diagnosed:	
-	Refusal	of	
asylum	
-	Obligation	to	
undergo	
preventive	
therapy	
-Other	
	
Obligation	to	
undergo	
preventive	
therapy:	
a.	proposed	
to	all	
positive	for	
LTBI		
b.	same	
procedure	as	
native	
nationals	
positive	for	
LTBI	
c.	therapy	
delivery	
d.	funding	
Regional/	
national	
specific	
programmes	
for	TB	
management	
in	refugees	
Yes/N	o	
Regional/	
national	
programmes		
to	provide	
sensitive	
services		
			Yes/No	
Special	
measures	to	
deal	with	
undocumented	
migrants	
Yes/No	
Discrepancy/ies	
between	
guidelines	and	
implementation	
Yes/No	
TB	
Management	
funding	
	
	
No	
Refusal	of	
asylum	
34/36	(94.4%)	
			
	
Yes	
Obligation	to	
undergo	
treatment	
			24/36	(66.6%)	
	
Other	
10/36	(27.7%)	
	
	
		Not	applicable	
a. 	
Treatment	in						
Hospital	
24/36	(66.6%)	
	
Not	applicable	
	8/36	(22.2%)	
	
	Not	answered	
		4/36	(11.1%)	
	
b.	
Treatment	
immediately	
started	after	
diagnosis	
											No	
Refusal	of	
asylum	
20/36	(55.5%)	
	
Yes	
Obligation	to	
undergo	
preventive	
therapy	
8/36	(22.2%)	
	
Other	
18/36	(50%)	
	
	
		Not	applicable	
a.	
	Proposed	to	
all	positive	for	
LTBI	
3/36	(8.3%)	
	
No,	proposed	
for	specific	
groups	and	
ages	only	
7/36	(19.4%)	
	
Not	
applicable	
24/36	(66.6%)	
	
Not	answered	
Yes	
10/36	(27.7%)	
	
No,		
not	fully	
specific	
		4/36	11.1%)	
	
No	
22/36(61.1%)	
Yes	
23/36(63.8%)	
	
										No	
1/36	(2.7%)	
	
Not	answered	
12/36	(33.3%)	
Yes	
22/36	(61.1%)	
	
													No	
				1/36	(2.7%)	
	
		Not	answered	
		13/36	(36.1%)	
Yes	
			9/36	(25%)	
	
No	
			6/36	(16.6%)	
	
	Not	answered	
			8/36	(22.2%)	
	
	Not	applicable	
		13/36	(36.1%)	
Government	
funds	
22/36	(61.1%)	
	
Not	answered	
12/36	(33.3%)	
	
Not	
applicable	
		2/36	(5.5%)	
2/36	(5.5%)	
	
26/36	(72.2%)	
	
Not	answered	
2/36	(5.5%)	
	
Not	applicable	
8/36	(22.2%)	
	
c.	
Governmental	
funds	
26/36	(72.2%)	
	
Not	answered	
		2/36	(5.5%)	
	
Not	applicable	
8/36	(22.2%)	
	
	
			8/36	(22.2%)	
	
						
	
	1/36	(2.7%)	
												
										b.	
Same	
procedure		
as	native	
nationals	
positive	for	
LTBI	
7/36(19.4%)	
	
Not	
applicable	
24/36(66.6%)	
	
Not	answered	
5/36	(13.8%)	
	
c.	
					Therapy	
delivered	at	
Chest/DOT/T
B	centres/TB	
specialists	
7/36	(19.4%)	
	
Not	
applicable	
23/36(63.8%)	
	
Not	answered	
6/36	(16.6%)	
	
d.	
Government	
budget	
			9/36	(25%)	
	
Not	
applicable	
23/36	(63.8%)	
	
Not	answered	
4/36	(11.1%)	
Footnotes:	TB:	tuberculosis;	LTBI:	latent	Tuberculosis	infection;	DOT:	direct	observed	therapy	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table	3:	Questionnaire	Section	III:	Guidelines,	Legislation	and	Evidence	on	the	results	of	screening	and	treatment	of	TB	and	LTBI	in	Europe	
Screening	and	
management	of	active	TB	
among	refugees	according	
to	national	or	
international	
guidelines/legislation	in	
force	
Yes/No	
Screening	and	
management	of	LTBI	
among	refugees	according	
to	national	or	
international	
guidelines/legislation	in	
force	
Yes/No	
Data	collection	in	
place	to	assess	
the	yield	of	
screening	for	
active	TB	among	
refugees	
Yes/No	
Data	collection	in	
place	to	assess	the	
yield	of	screening	for	
LTBI	among	refugees	
Yes/No	
Data	collection	in	
place		to	assess	
treatment	success	
rates	of	active	TB	
among	refugees	
Yes/No	
Data	collection	in	
place	to	assess	
completion	rates	of	
LTBI	among	refugees	
Yes/No	
	
Yes	
27/36	(75%)	
	
	
Yes	
19/36	(52.7%)	
	
Yes	
18/36	(50%)	
	
Yes	
8/36	(22.2%)	
	
	
Yes	
19/36	(52.7%)	
	
	
	
																Yes	
8/36	(22.2%)	
No	
3/36	(8.3%)	
	
No	
7/36	(19.4%)	
Yes	partially	or	
not	systematically	
4/36	(11.1%)	
	
Yes	partially	or	
not	systematically	
3/36	(8.3%)	
	
No	
10/36	(27.7%)	
	
No	
20/36	(55.5%)	
											Not	applicable	
1/36(2.7%)	
	
Not	answered	
5/36	(13.8%)	
	
Not	applicable	
5/36	(13.8%)	
	
Not	answered	
5/36	(13.8%)	
No	
8/36	(22.2%)	
	
Not	answered	
4/36	(11.1%)	
	
Not	applicable	
2/36	(5.5%)	
No	
18/36	(50%)	
	
Not	answered	
4/36	(11.1%)	
	
Not	applicable	
3/36	(8.3%)	
	
	
Not	answered	
6/36	(16.6%)	
	
Not	applicable	
1/36	(2.7%)	
	
	
	
Not	answered	
6/36	(16.6%)	
	
					Not	applicable	
2/36	(5.5%)	
Footnotes:	TB:	tuberculosis;	LTBI:	latent	Tuberculosis	infection	
	
	
Table	4:	Questionnaire	Section	IV:	Organisational	aspects	of	TB	care	and	infection	control	issues	
N.	of	refugees	hosted	
at	the	national	level	
during	the	last	6	
months	
-	<50,000	
-	50,001	–	100,000	
-	100,001	–	250,000	
-	>250,000	
Organisation(s)	
responsible	for	first-line	
medical	care	of	refugees	
at	the	national	level		
Special	
measures	for	
cross-border	
care	when	a	
refugee	is	
diagnosed	
active	TB	
						Yes/No	
Priority	problems	identified	at	the	
national	level	to	manage	TB	among	
refugees	
Personal	protection/	infection	control	measures	in	
place	for	presumptive	active	TB	cases	
-	No	specific	measures	in	place	
-	Respirators	used	for	staff	in	contact	with	refugees	
-	Respirators	used	for	staff	and	surgical	masks	for	
individuals	with	possible	TB	or	other	respiratory	
disease	
-	Other	
<50,000	
25/36	(69.4%)	
	
50,001	–	100,000	
2/36	(5.5%)	
	
100,001	–	250,000	
1/36	(2.7%)	
	
>250,000	
7/36	(19.4%)	
	
Not	answered	
1/36	(2.7%)	
	
National	and/or	local	
medical/public	health	
services	(including	
Ministry	of	Health)	
								21/36	(58.3%)	
	
Medical	staff	of		holding	
centres	
3/36	(8.3%)	
	
Primary	health	care	clinics	
3/36	(8.3%)	
	
Federal	/State	Agencies		
for	Refugees	
3/36	(8.3%)	
	
Red	Cross/International	
Organizations	
6/36	(16.6%)	
	
Public/private	providers	
1/36	(2.7%)	
	
Yes	
17/36	(47.2%)	
	
No	
14/36	(38.8%)	
	
Not	answered	
				3/36	(8.3%)	
	
Not	applicable	
				2/36	(5.5%)	
System	in	place	overloaded	by	the	
recent	increase	of	migrants/	
Suboptimal	coverage	of	screening	
and	contact-tracing	(high	screening	
numbers,	separate	registers)	
Organizations	/Public	Health	services	
understaffed	regarding	the	workload	
(delay	and	difficulties	in	diagnosis,	
treatment,	care	and	follow	up/	
Treatment	&.care/	organise	cross-
border	care	/low	compliance	,	many		
lost-to-follow-up	under	TB	treatment	
and	continuing	migration	mobility	
																		22/36	(61.1%)	
	
Major	barriers	to	access	health	care	
services	related	to	cultural,	religious,	
and	language	differences/	lack	of	
knowledge	about	TB,	lack	of	
information	about	the	healthcare	
system	in	the	country	and	cultural	
constraints/Stigmatization	of	TB	
patients/	insufficient	patient	
counselling	and	motivation	
Respirators	used	for	staff	and	surgical	masks	for	
individuals	with	possible	TB	or	other	respiratory	
disease	
																																				24/36	(66.6%)	
	
Only	Respirator	used	for	staff	in	contact	with	refugees	
1/36	(2.7%)	
	
Other	
7/36	(19.4%)	
	
Not	answered	
4/36	(11.1%)	
	 													13/36	(36.1%)	
	
Lack	of	coordination	among	involved	
entities	
																6/36	(16.6%)	
	
														Logistical	problems	
																	10/36	(27.7%)	
	
Footnotes:	TB:	tuberculosis	
 
